Drug Patch Manufacturers Can Skip Quality By Design Approach, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Final guidance softens a recommendation that manufacturers of transdermal and transmucosal drug delivery systems and topical patches use a Quality by Design approach.